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Multiple Sclerosis (MS) is a chronic neurological disease 
of the central nervous system and is potentially the most 
common cause of neurological disability in young adults.1 
The disease course is characterized by either acute periods 
of deterioration or relapses (about 85% of patients initially), 
or gradual progressive deterioration of neurological func-
tioning, or combinations of the two.
Understanding the course of chronic diseases is a recur-
rent objective in research. Natural history studies, for 
example, are follow-up studies that provide the strongest 
evidence. These studies thoroughly examine the course of 
the disease among a large number of patients for a period of 
about 30–40 years. Natural history studies in MS have 
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Background: Evidence on the progress of disease severity in Multiple Sclerosis (MS) is generally limited in scope.
Objectives: To examine the course of a broad spectrum of MS-related disabilities and quality of life (QOL) in relation 
to disease severity, and responsiveness of the Multiple Sclerosis Impact Profile (MSIP). 
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Netherlands. We assessed these patients in 2004 and 2009 using a postal survey including the MSIP to evaluate disabilities, 
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Results: Increase of disability in the MSIP disability domains and loss of QOL were most prevalent and pronounced 
in patients with EDSS 0 to < 4.5 in 2004. MSIP and QOL scores were remarkably stable in the higher disease severity 
groups. Mortality rates were highest (24%) in patients with EDSS ≥ 7 to < 10 in 2004. SRM indices for the MSIP ranged 
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resulted in clearly defined courses of the disease and identi-
fied landmarks or disability milestones related to these 
courses. Milestones are clinically detectable thresholds of 
irreversible disability in the disease process regarding MS, 
usually defined using the Expanded Disability Status Scale 
(EDSS).2 Examples of these milestones are EDSS score 4 
(limited walking but without aid), score 6 (walking with 
unilateral aid) and score 7 (wheelchair-bound). Two 
recently published studies reported comparable findings 
about the relationship between age and reaching disability 
milestones. Confavreux and Vukusic3 followed a cohort of 
patients with MS (n = 1844) for about 30 years and esti-
mated the median age at reaching milestones: 44 years for 
EDSS score 4, 55 years for score 6, and 63 years for score 
7. Kremenchutzky et al. 4 followed a cohort of patients (n = 
505) for about 25 years and found, despite considerable 
individual variation, that the mean age at reaching EDSS 
score 4 was 40 years. From the first milestone onwards, 
time between disability milestones was remarkably compa-
rable with the findings of Confavreux and Vukusic.3
Studies with a shorter follow-up period have provided 
weaker evidence than did natural history studies. Another 
difference compared with natural history studies is that 
results in these studies took into account the recently avail-
able disease-modifying therapies. Pittock et al.,5 for exam-
ple, studied the change in disability over 10 years in a 
cohort of 161 patients with MS, of which 15% had received 
immunomodulatory therapy. Some 30% of these patients 
progressed, while most patients remained stable or mini-
mally progressed. Trojano et al.6 examined the impact of 
interferon-beta on disease progression in patients with 
relapsing–remitting MS (n = 1504) during a 7-year follow-
up study and found significant delays in reaching disability 
milestones (EDSS scores 4 and 6). Bermel et al.7 examined 
122 patients an average of 15 years after participation in an 
interferon trial and found that EDSS scores highly corre-
lated with quality of life (QOL) and self-care independ-
ence. Finally, Stenager et al. found at 5-year follow-up a 
significant increase in the number of acute and chronic pain 
syndromes8 and sexual dysfunction,9 especially in patients 
with increasing disability, while Pfleger and colleagues 
reported a negative impact of MS on economic aspects of 
living even within a few years of disease onset.10,11
Evidence on long-term follow-up of QOL among 
patients with MS is lacking, but cross-sectional studies 
have shown that MS patients experience lower levels of 
QOL than the general population.12,13 MS-related symp-
toms and disabilities are a likely explanation for this 
reduced QOL. This has been demonstrated for a number of 
symptoms and disabilities, such as fatigue,14-16 cognitive 
and emotional functioning,17 depression,14,15,18,19 chronic 
pain,20 and bladder and sexual dysfunction.21
Risk of suicide, probably related with a poor QOL, 
among persons with MS is about three times higher during 
the first years after diagnosis as expected in the general 
population.22 Furthermore, among patients diagnosed with 
MS more than 20 years ago, the suicide risk is almost twice 
as high as expected, probably because these patients expe-
rience the most serious consequences of the disease.22
In our previous study,23 in which we examined the rela-
tive impact of MS-related disabilities on QOL, using the 
Multiple Sclerosis Impact Profile (MSIP) we found that 
impairment in mental functioning was the most important 
predictor for QOL.
The MSIP is a disability measure based on the 
International Classification of Functioning, Disabilities 
and Health (ICF).24 Items for the MSIP were selected by a 
expert panel (n = 98) consisting of patients and proxies, 
medical and non-medical experts.25 The MSIP is an out-
come measure reflecting MS-specific disabilities meeting 
psychometric criteria concerning reliability (internal con-
sistency, mean inter-item correlation and test–retest relia-
bility) and validity (convergent, discriminant, known 
groups and relative validity).26,27 Concerning relative 
validity, the MSIP was more sensitive and more powerful 
in detecting differences between disease severity sub-
groups and QOL subgroups than generic QOL measures. 
Advantages of the MSIP compared with other disease-
specific measurements such as the EDSS2,28 or the Multiple 
Sclerosis Impact Scale (MSIS-29)29,30 are that the MSIP 
combines psychometric quality with a broad assessment of 
MS-related health problems in more detail. The most 
important limitation in evaluating the MSIP properties was 
that we could not examine the responsiveness, the ability 
of a measure to detect change over time. Although relative 
validity is a good indicator for sensitivity to change, this 
does not substitute for responsiveness tests. Therefore, 
because this is the first longitudinal study in which we 
used the MSIP, we estimated the responsiveness.
In summary, previous longitudinal studies generated 
important information about progress in disease severity but 
are limited for several reasons. First, regarding disability, 
they have mainly reported about limitations in walking and 
provided limited information about other clinically relevant 
MS-related disabilities. Second, these studies rarely include 
the course of QOL during disease progression. Therefore, 
the objective of this study was to examine the course of a 
broad spectrum of MS-related disabilities and QOL in rela-
tion to disease severity. Because longitudinal studies are not 
complete without a detailed analysis of patients passing dis-
ability milestones and MS-related mortality rate, we also 
examined the characteristics of patients who passed disabil-
ity milestones and calculated the mortality rate.
Methods
Design
We performed a 5-year follow-up study in a cohort of 276 
patients with MS initially assessed in 2004.
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Patients and procedures
Our initial sample in 2004 consisted of 378 MS patients 
attending the Groningen MS Center, part of the Neurology 
department of the University Medical Hospital Groningen 
in the Netherlands. These patients were checked for vital 
status using the national population register. This yielded 
31 deaths (8%) during the 5-year period. The remaining 
patients were eligible for follow-up re-assessment in 2009 
and received a postal invitation to participate in the survey 
and to answer demographic and disease-related questions, 
and to complete questionnaires for disease severity, a broad 
range of MS-related disabilities and QOL. Non-responders 
received a reminder after 2 weeks.
Of the 347 patients in our follow-up re-assessment, 245 
patients (71% response rate) completed the questionnaires. 
The 102 non-responders did not differ from the responding 
patients regarding age, gender, marital status, educational 
level and years since MS diagnosis.
Measures
To evaluate disease severity we used the Ambulation ques-
tion from the self-report version of the EDSS.31 The EDSS 
score is an ordinal variable starting at 0 (no disability) and 
increasing at half point increments to a maximum score of 
10 (death due to MS). The Ambulation question reflects 
EDSS scores in the range 4.5–10.31
For this study, patients were classified into three clini-
cally relevant and recognizable ‘disease severity sub-
groups’: the low-severity subgroup (EDSS 0 to < 4.5) 
comprising persons able to walk more than 500 m with no 
assistance; moderate-severity subgroup (EDSS ≥ 4.5 to < 7) 
comprising persons limited in walking; and high-severity 
subgroup (EDSS ≥ 7 to < 10) comprising persons at least 
partially restricted to a wheelchair or bed. We defined 
‘passing a disability milestone’ as the progress to the next, 
more severe, disease severity subgroup.
We applied the Measures (MSIP) to assess MS-related 
disabilities.26,27 The MSIP measures the prevalence and 
severity of a broad range of MS-related disabilities con-
cerning body functions, execution of activities by the indi-
vidual, involvement in life situations and lack of support 
from the environment. It consists of 36 items divided over 
seven scales and four additional impairment items (fatigue, 
pain and impairment in seeing functions and impairment in 
speech functions). Scoring options range from 0 (no disa-
bility/full support) to 3 or 4 (complete disability/no sup-
port). Summed scores for each scale indicate the extent of 
disability or lack of support from the environment. For the 
purpose of this study the sum scores and the scores on the 
single impairment items were multiplied to obtain a result 
ranging from 0–100. The internal consistency tests of the 
MSIP scales were good for most scales (Cronbach’s alphas: 
0.80 and 0.90), satisfactory for the ‘Mental functioning’ 
scale (0.62) and weak for the ‘Environmental factors’ scale 
(0.49). Mean inter-item correlation coefficients were good 
for both ‘Mental functioning’ scale (0.35) and 
‘Environmental factors’ scale (0.19).26,32
To measure QOL we applied the World Health 
Organization Quality Of Life, abbreviated version 
(WHOQOL-BREF), a generic QOL measure with a broad 
scope, including environmental aspects. It consists of 26 
items, divided into four domains covering ‘Physical health 
and autonomy’, ‘Psychological health’, ‘Social relation-
ships’ and ‘Environmental aspects’ and has two single-item 
questions (‘Overall quality of life’ and ‘Overall satisfaction 
with health’). For each scale, item scores were coded, 
summed and transferred to a scale of 0 (worst health) to 20 
(best health). In our previous study in patients with MS the 
WHOQOL-BREF showed satisfactory levels of internal 
consistency with Cronbach’s alpha between 0.63 and 0.81.26
Analysis
To calculate the mortality rate in our 2004 cohort these 
patients were checked for vital status using the national 
population register.
For comparison of mean scores for demographic and 
disease-related variables between groups of respondents 
and non-respondents, and between deceased patients and 
survivors, we used t-tests for continuous variables and non-
parametric tests to compare scores on ordinal variables. 
The difference of proportions test was used to compare 
scores on nominal variables. To examine the changes dur-
ing the 5-year period concerning disabilities and QOL we 
used the paired samples t-test.
Responsiveness of the MSIP was estimated by the stand-
ardized response mean (SRM) for assessing of an outcome 
measure’s ability to detect change over time. In the SRM 
formula, the mean change in scores over time are divided 
by the standard deviation (SD) of these change scores. 
Next, with the aim to quantify the change in disability and 
QOL over time as ‘trivial’, ‘small’, ‘moderate’ or ‘large’, 
the Effect Size (ES) indicator was used (mean change in 
scores over time divided by the pooled SD of baseline and 
follow-up scores). According to Cohen’s thresholds33 an ES 
of < 0.20 indicates a trivial change, an ES of ≥ 0.20 to < 
0.50 a small change, an ES of ≥ 0.50 to < 0.80 a moderate 
change, and an ES ≥ 0.80 a large change. These two meth-
ods of standardizing mean changes in outcomes were used 
since the interpretation of the SRM with Cohen’s thresh-
olds34 leads to overestimation or underestimation, as these 
thresholds were developed on standardizing mean differ-
ences between baseline and follow-up by using the pooled 
standard deviation (SDp). It has been convincingly argued 
that only the SDp should be used to interpret ES for corre-
lated designs.35,36
All statistical tests were two-tailed. A value of p < 0.05 
was used for all tests to indicate statistical significance. 
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SRM and ES were calculated for statistically significant 
differences. It was shown that, according to an external cri-
terion, SRM ≥ 0.20 reflects a clinical relevant change.37
Results
Cohort
Demographic and disease-related characteristics of the 245 
participants in both measurements in 2004 and 2009 are 
presented in Table 1. Four patients were excluded from fur-
ther analysis because their EDSS scores were not known.
Sensitivity to change over time
Nine of the 11 MSIP disability domains were able to detect 
change over time (See Table 2), while three of the four 
WHOQOL-BREF scales were, due to random variation 
(p > 0.05), not able to detect change over time.
Overall change in disability profile and QOL
The overall cohort showed a statistically significant and 
clinically relevant increase in disability in eight out of 11 
MSIP disability domains when compared with baseline 
(Table 2). ‘Lack of support from environmental factors’ 
showed the largest, but moderate increase, followed by 
‘Impairment in speech’ and both ‘limitations in activities’ 
domains with a small increase.
Patients reported a small worsening in QOL concerning 
‘Physical health and autonomy’ compared with 5 years 
earlier.
Change in disease severity, disability profile 
and QOL in the low disease severity 
subgroup (EDSS 0 to < 4.5)
In total 96 patients in the low disease severity subgroup in 
2004 participated in both measurements. After 5 years 66 
patients (69%) were still unlimited in walking. MS was 
leading to limitations in walking for 18 patients (19%): 
median age in 2004 for these patients was 44.5 years (range 
27–68 years). MS was leading to wheelchair dependency 
for 12 patients (13%): median age in 2004 was 46 years 
(range 35–67 years).
Patients in this subgroup showed an increase in disabil-
ity in seven out of 10 MSIP disability domains (Table 3). 
‘Lack of support from environmental factors’ showed a 
moderate increase. All other changes were of a small mag-
nitude and concerned ‘Impairments in body functions’, 
‘Limitations in activities’, and ‘Restrictions in participation 
in life situations’.
Patients reported a small worsening in QOL concerning 
‘Physical health and autonomy’ and a trivial worsening in 
quality of ‘Psychological health’ and quality of the 
‘Environment’ compared with 5 years earlier.
Change in disease severity, disability profile 
and QOL in the moderate disease severity 
subgroup (EDSS ≥ 4.5 to < 7)
In total 99 patients with moderate disease severity in 2004 
participated in both measurements. During the intervening 
5 years the mean EDSS score increased from 6.0 to 6.5 
(p-value 0.000). After 5 years 51 patients (52%) experi-
enced ambulatory limitations but were still able to walk, 
while disease severity in 35 patients (35%) increased to 
wheelchair dependency. Median age in 2004 for these 
patients was 51 years (range 29–69 years). Walking ability 
improved for 13 patients (13%) who reported being not 
limited in walking.
Patients in this subgroup showed a clinically relevant 
increase in disability in five out of 10 MSIP disability 
domains (Table 3). ‘Lack of support from environmental 
factors’ showed a moderate increase. All other changes 
were of a small magnitude and concerned ‘Impairment in 
speech functions’, ‘Limitations in activities’, and 
‘Restrictions in participation in life situations’.
QOL among patients in this subgroup did not change 
during the 5-year period.
Table 1. Patients characteristics of participants in both 
measures in 2004 (n = 245)
Cohort
Gender (%)
 Female 165 (67)
 Male 80 (33)
Age
 Mean (SD) 51 (11)
 Range  23–85
Marital status (%)
 Married / partnership 196 (81)
 Unmarried / widowed / divorced 45 (19)
Educational level (highest level) (%)
 Primary or secondary school / vocational training 188 (77)
 Higher professional education / university 54 (23)
Employment status (more answers possible) (%)
 Employment 59 (24)
 Voluntary work 14 (6)
 (partially) retired due to MS 144 (60)
 Housewife / househusband 74 (31)
 Retired due to age 25 (10)
Years since MS diagnosis
 Mean (SD) 13 (8)
 Range  1–42
EDSS score (range 0–10) (%)
 0 to < 4.5 96 (39)
 ≥ 4.5 to < 7 99 (40)
 ≥ 7 to < 10 46 (19)
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Change in disease severity, disability profile 
and QOL in the high disease severity 
subgroup (EDSS ≥ 7 to < 10)
In total 46 patients within this subgroup participated in both 
measurements. During the intervening 5 years the mean 
EDSS score of these patients increased from 8.5 to 9.0 
(p-value 0.001). After 5 years 44 patients (96%) in this sub-
group were still wheelchair dependent, while two patients 
(4%) improved and were able to walk while using assist 
devices.
Patients showed a small increase in ‘Impairment in 
speech functions’ (Table 3). Other MSIP disability domains, 
as well as all QOL domains, did not change during the 
5-year period.
Mortality rates
From the 378 patients in our original cohort 31 patients 
(8%) had died in 2009: 15 female and 16 male patients. 
Mean age at time of death was 58.1 years (SD 14.0, range 
33–83 years) for the total sample of patients who had 
deceased in the period 2004–2009. There was no difference 
between male and female patients. The mortality rate was 
highest in the highest disease severity subgroup: out of the 
89 MS patients with EDSS ≥ 7 to < 10 in 2004, 21 patients 
(23.6%) died. Out of the 138 MS patients with EDSS ≥ 4.5 
to < 7 in 2004, eight patients (5.8%) died, and among the 
143 MS patients with EDSS 0 to < 4.5 in 2004, two patients 
(1.4%) were deceased.
Discussion
In this study we found that the increase of disability in the 
MSIP domains and loss of QOL were most pronounced in 
the low disease severity subgroup (EDSS 0 to < 4.5), while 
there was no clinically relevant increase of MSIP disabili-
ties or worsening of QOL in the highest disease severity 
subgroup (EDSS ≥ 7 to < 10). Concerning the progress of 
disease severity, we found that the median age of patients 
who passed the first disability milestone (EDSS 4) was 44 
years in 2004 and of patients who passed the second disa-
bility milestone (EDSS 7) was 51 years in 2004. As 
expected, mortality was highest (24%) among those in the 
highest disease severity subgroup in 2004.
We examined the responsiveness of the MSIP. The MSIP 
was shown to be sensitive to detect change over time for 9 out 
of 11 MSIP domains. Compared with the WHOQOL-BREF, 
the MSIP performed better in detecting changes over time.
Our study was the first to examine the change in a broad 
spectrum of MS-related disabilities using the MSIP. We 








 Muscle and Movement Functions 28.3 (21.2) 2.3 (15.0) 0.26
 Excretion and Reproductive Functions 28.2 (23.5) 3.7 (16.7) 0.32
 Mental Functions 21.5 (17.8) 0.9 (14.3) ns
 Speech functions  6.3 (13.0) 4.7 (13.9) 0.26
 Seeing functions 18.6 (22.3) 3.3 (22.3) 0.27
Fatigue 45.2 (23.2) 4.0 (21.8) 0.56
Pain 22.5 (23.5) 0.8 (18.9) ns
Limitations in …
 Basic Movement Activities 29.0 (29.3) 7.1 (19.3) 0.53
 Activities of Daily Living 32.6 (30.1) 7.1 (18.1) 0.55
Restrictions in …
 Participation in life situations 16.9 (22.5) 2.7 (21.2) 0.48
Lack of support in …
 Environmental Factors 19.7 (22.0) 11.6 (27.2) 0.51
WHOQOL-BREF
Physical Health and Autonomy 13.9 (2.8) −0.6 (2.6) 0.33
Psychological Health 14.4 (2.5) −0.2 (2.1) ns
Social Relations 15.0 (3.0) −0.3 (3.9) ns
Environment 15.5 (2.4) −0.2 (2.6) ns
SRM, Standardized Response Mean;
MSIP (range 0–100): higher scores = more disability / less support;
WHOQOL-BREF (range 0–20): higher scores = better Quality of life;
ns = not significant
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found that the increase of disability in the MSIP disability 
domains was most prevalent and most pronounced in the 
low disease severity subgroup. We also found that there 
was no clinically relevant increase of MSIP disabilities or 
worsening of QOL in the highest disease severity subgroup 
and a moderate increase of disabilities in the moderate dis-
ease severity subgroup. This study also was the first to 
examine change in QOL in MS over time. Again, we found 
that the lowest disease severity group was the group that 
seemed to suffer most. QOL in this group worsened for all 
domains, except for the domain of ‘Social relations’, while 
QOL in the other subgroups did not change.
Our findings that the low disease severity group experi-
enced the largest increase in disability and the largest loss 
in QOL may be an explanation for the high suicide risk 
during the years after diagnosis.22 Therefore, these findings 
suggest that patients who are in the first phase of the dis-
ease process might be in more need for support from the 
health care system than is generally expected. Our finding 
that patients in the low disease severity subgroup might 
need more support was confirmed by the high increase in 
the MSIP domain ‘Lack of support from the environment’ 
(support from family, professionals, social and health care 
systems) in both the lowest and moderate disease severity 
subgroups, while the patients in the highest disease severity 
subgroup showed no increase in lack of support. This find-
ing is likely to apply to all developed countries. Although 
the introduction of immunomodulatory treatment may have 
resulted in more support to eligible patients in the low-
severity group, despite this additional support (that focuses 
on the therapy and side effects of therapy) patients are still 
reporting a lack of support from the environment in this 
early disease stage. For the broad range of consequences of 
MS, a more integrated, patient-centred, proactive and pre-
ventive care system is needed.
Our finding of a median age of 44 years for patients who 
passed the first disability milestone (EDSS 4) was similar 
to that found by Confavreux and Vukusic3 and 
Kremenchutzky et al.4 However, the median age of 51 years 
for passing the disability milestone EDSS 7 was lower than 
Table 3. Changes over 5 years in disabilities and QOL in the disease severity subgroups (n = 241)
EDSS score 0 to <4.5 (n = 96) EDSS score ≥4.5 to <7 (n = 99) EDSS score ≥7 to <10 (n = 46)
 2004 Change 2004 Change 2004 Change  
 Mean (SD) Mean (SD) ES Mean (SD) Mean (SD) ES Mean (SD) Mean (SD) ES
MSIP Disabilities
Impairments in …
 Muscle and Movement 
Functions
13.0 (13.2)  5.4 (10.0) 0.40 30.9 (13.6)  0.0 (14.0) ns 54.2 (21.6)  0.7 (23.4) ns
  Excretion and  
Reproductive Functions
15.9 (17.0)  3.5 (11.9) 0.20 31.6 (19.2)  3.7 (16.0) ns 52.8 (27.4)  4.2 (27.3) ns
 Mental Functions 16.7 (18.1)  1.6 (14.1) ns 24.6 (17.1)  0.4 (13.9) ns 26.1 (16.4)  0.5 (16.2) ns
 Speech functions  4.7 (10.5)  2.2 (9.6) 0.20  4.7 (9.8)  3.6 (11.5) 0.30 14.0 (19.9) 12.2 (22.1) 0.47
 Seeing functions 13.7 (15.9)  1.1 (16.6) ns 18.3 (21.1)  5.0 (24.6) ns 29.2 (31.2)  5.4 (27.4) ns
Fatigue 35.5 (21.6)  6.5 (20.2) 0.27 51.0 (19.2) −0.8 (19.7) ns 54.6 (27.4)  8.1 (27.7) ns
Pain 15.9 (21.9)  2.2 (18.5) ns 28.3 (23.8) −1.9 (19.0) ns 25.0 (23.4)  3.6 (20.3) ns
Limitations in …
  Basis Movement  
Activities
 7.8 (10.8)  5.7 (15.8) 0.39 27.8 (18.3)  9.6 (22.7) 0.45 73.6 (24.1)  4.9 (18.0) ns
  Activities of Daily Living  9.6 (11.1)  6.1 (16.4) 0.38 33.2 (19.5) 10.3 (19.6) 0.47 80.2 (19.3)  2.0 (17.7) ns
Restrictions in ….
  Participation in life  
situations
 6.0 (10.0)  4.1 (15.0) 0.32 16.6 (18.3)  4.8 (20.9) 0.25 45.1 (29.9) −6.1 (31.3) ns
Lack of support from
 Environmental Factors 26.4 (26.1) 16.0 (30.1) 0.60 17.6 (20.2) 13.7 (26.1) 0.65 15.2 (18.0)  1.9 (24.3) ns
WHOQOL-BREF
Physical Health and  
Autonomy
15.5 (2.7) −0.9 (2.5) 0.36 13.2 (2.2) −0.2 (2.3) ns 11.8 (2.5) −0.6 (3.2) ns
Psychological Health 15.1 (2.6) −0.6 (2.0) 0.19 14.2 (2.3) −0.0 (2.0) ns 12.9 (2.3) −0.0 (2.3) ns
Social Relations 15.5 (3.1) −0.5 (2.7) ns 15.2 (2.6) −0.4 (2.8) ns 13.2 (3.0)  0.4 (3.4) ns
Environment 16.5 (2.5) −0.5 (2.2) 0.15 15.1 (2.0) −0.1 (1.8) ns 14.1 (2.2)  0.1 (2.5) ns
ES = Effect Size; MSIP (range 0–100): higher scores = more disability / less support;  WHOQOL-BREF (range 0–20): higher scores = better Quality of 
life; ns = not significant
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reported in the studies of Confavreux and Vukusic,3 who 
found a median age of 63 years, and Kremenchutzky et al.,4 
who found that time between disability milestones was 
‘remarkably comparable’ with the findings of Confavreux 
and Vukusic.3 These findings may be indicative of the fact 
that advances in disease severity in our cohort were faster 
than in the natural history studies. There are several reasons 
that could explain this difference. First, there is an ongoing 
discussion about when progression in MS can be defined as 
‘sustained progression’. Kremenchutzky et al.4 even sug-
gested that a final decision that recovery from exacerba-
tions does not occur is just possible after a year of follow-up. 
Our finding that 15 patients in the 2004 cohort were recov-
ered to a lower, less severe, disease severity subgroup fits 
with this. Furthermore, the precision of the results in our 
study concerning the median age at time of passing a disa-
bility milestone is limited due to the fact that the exact 
moment of passing the milestone is ‘somewhere’ between 
both measurements. Second, the range between minimum 
and maximum age for passing a milestone in our sample 
was large (about 40 years), a finding that was also reported 
by Kremenchutzky et al.4 Nevertheless, this broad range 
might affect the median age. Finally, our findings are based 
on self-report questionnaires. Although this method is rec-
ognized as a valid and reliable method, results are similar 
but not equal to observation-based measures.
Mortality was highest (24%) among those in the highest 
disease severity subgroup, while there was a increase in 
disease severity but no increase in disability profile among 
survivors in this subgroup. Mean age at time of death in our 
cohort was 10 years lower (55 years, SD 14) compared with 
the results in the study of Hirst et al.,38 who found a mean 
age of 65 years (SD 15). This finding, in combination with 
a relatively shorter time between two disability milestones, 
could suggest that progress of disease severity in our cohort 
was relatively stronger compared with findings in other 
studies.
There are some (potential) limitations in this study. First, 
there is the lack of information about the use of immu-
nomodulatory treatment among patients in our cohort. This 
treatment may have a positive impact on the course of the 
disease,6,7 and on the time before and between disability 
milestones. Another limitation was the incompleteness and 
limited quality of the information on causes of death that 
we obtained regarding our cohort.
In summary, we succeeded in examining the course of a 
broad range of MS-related disabilities and QOL in relation 
to disease severity. This information resulted in a precise 
insight into the consequences of MS, and subsequently pro-
vided valuable information that can guide the selection of 
health care interventions. The responsiveness of the MSIP, 
which is a relatively new measure, was found to be suffi-
cient for 9 out of the 11 MSIP domains.
Based on our findings we conclude that prominent 
increases in multiple aspects of disability and loss of QOL 
occur in early stages in MS in particular. Health care inter-
ventions may lead to large health and QOL gains in particu-
lar when offered to patients who are in the first stage of the 
MS process. Furthermore, health care professionals should 
be aware of the high risk of death in the high disease sever-
ity subgroup.
Based on our findings we recommend that future 
follow-up studies include a detailed assessment of disabili-
ties and QOL for a better understanding of the consequences 
of MS. Furthermore, with this broader range of disease-
related variables more options are available for prognostic 
studies with the aim to select predictive variables and to 
assess their impact on disease progression.
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